SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending after its Q4 earnings report, which largely surpassed estimates, yet the stock saw a significant decline. Community discussion is polarized, with bulls viewing the dip as an oversold opportunity, highlighting strong subscriber growth and accelerating ad revenue. Conversely, bears are focused on cautious forward guidance, increased content spending, and the pause in share buybacks tied to a potential major acquisition, fueling concerns about near-term shareholder value.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is trending due to surging natural gas futures prices, driven by forecasts of an extensive arctic cold snap and polar vortex across the US. This weather-driven demand is igniting a significant short squeeze, with the community actively discussing potential further upside and extreme volatility for leveraged natural gas products.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is experiencing a powerful rally to record highs, driven by heightened geopolitical tensions, particularly concerns surrounding President Trump's tariff threats against European allies over Greenland. The community is actively discussing gold's role as a vital safe-haven, with many viewing it as a critical hedge against market instability and potential dollar weakness in a "risk-off" environment. This reflects a broad shift towards tangible assets amidst global uncertainty.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is driving significant conversation due to recent analyst upgrades and reports of a substantial U.S. SHIELD defense contract, further highlighting its strategic importance in domestic chip manufacturing. The community is actively discussing expectations for an upcoming earnings report, with sentiment boosted by reports of Intel's 2026 server CPU capacity being largely sold out amidst growing AI demand.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is experiencing extreme volatility and a significant decline, as natural gas prices surge on forecasts predicting colder U.S. weather and heightened heating demand, triggering a notable short squeeze. The community is actively discussing KOLD's dramatic daily drops and the rapid ascent of its inverse, highlighting the "widowmaker" nature of natural gas markets as traders navigate this weather-driven rally.

America's Oil Reserve for the Digital Age

U.S Oil

USOR CRYPTO is experiencing extreme volatility and highly polarized community sentiment, with many labeling it a 'rug pull' or 'pump and dump' after sharp price movements. Despite these strong warnings, a segment of the community remains aggressively bullish, anticipating massive gains and a significant event by early February. The ongoing debate also highlights widespread confusion and questions regarding legitimate buying avenues and potential fake tokens.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is experiencing a notable price pullback, sparking intense debate among the community, with some advocating to "buy the dip" given historically oversold technical indicators and anticipated strong iPhone demand ahead of upcoming earnings. However, others remain cautious, pointing to broader market "risk-off" sentiment fueled by geopolitical tensions and ongoing concerns regarding Apple's long-term growth prospects and AI innovation compared to peers.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is currently trending due to compelling positive Phase 1 clinical trial data for its eczema drug, soquelitinib, demonstrating significant efficacy even in treatment-resistant patients. This promising data has sparked community discussions about the drug's blockbuster potential and the possibility of future partnerships within the large atopic dermatitis market. However, sentiment is divided as a recently announced public offering raises concerns about potential dilution, weighing on the stock's performance despite the favorable clinical results.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending due to reports of Zydus Lifesciences considering a significant equity stake or acquisition, following a critical patent extension for its key products until 2041. The community is actively discussing a potential bidding war, believing the company's strong revenue trajectory and extended intellectual property runway make it considerably undervalued. Many see the patent extension as a "game changer," significantly enhancing the company's long-term appeal to major pharmaceutical players.

Constellation Software Inc

Constellation Software (CSU.TSX) is a major talking point amid its deepest historical drawdown, sparking intense debate among investors. While many view the current valuation as an attractive buying opportunity, bolstered by recent strong financial results and analyst support, others are concerned about the broader impact of AI on the software sector, questioning the stock's immediate recovery potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company posted a net income available to common shareholders of $89.1 million, compared to a net loss of $286.4 million in the third quarter 2024.</li><li>Its revenue also jumped to $277.9 million, compared to $175.4 million in the third quarter 2024.</li><li>The company said strong financial performance in the third quarter was led by the Capital Markets segment.&nbsp;</li></ul>BRC Group Holdings, formerly known as B.Riley Financial, rallied in after-market hours on Wednesday after it announced its delayed quarterly results.&nbsp;The company filed financial reports for three quarters within 120 days, achieving NASDAQ compliance ahead of the deadline, it said in a regulatory filing.&nbsp;<h2 class="st-heading-2">Q3 Results</h2>The company posted a net income available to common shareholders of $89.1 million, compared to a net loss of $286.4 million in the third quarter 2024. The company said basic and diluted earnings per common share were $2.91 compared to a loss per share of $9.39 in the third quarter 2024.Its revenue also jumped to $277.9 million, compared to $175.4 million in the third quarter 2024. The company said strong financial performance in the third quarter was led by the Capital Markets segment with $65.4 million in services and fee revenues, the highest quarterly total since the fourth quarter of 2023.“We are pleased with the third quarter financial results. B. Riley Securities had a very strong quarter across investment banking, advisory, and research and trading with equity and debt capital raises totaling approximately $10.5 billion while delivering product innovation,” Bryant Riley, Chairman and Co-Chief Executive Officer of BRC, said.&nbsp;“Our Communications segment produced strong cash flow, consistent with previous quarters. B. Riley Wealth enhanced products and services for clients, while reducing costs and integrating its back office,” he added.&nbsp;<h2 class="st-heading-2">B.Riley Woes</h2>BRC’s struggles to file timely earnings reports started after a turbulent period in 2024 when it grappled with soured investments, flaws in financial reporting and a U.S. civil investigation.Franchise Group was a key investor of BRC and its bankruptcy in late 2024 left B. Riley burdened with write-offs of hundreds of millions of dollars and it was unable to file its annual and quarterly reports with US regulators on a timely basis. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around RILY trended in ‘extremely bullish’ territory amid ‘high’ message volume.&nbsp;One user predicted the stock could hit $15 on Thursday.<a href="https://stocktwits.com/SelectiveTrader/message/641848445">https://stocktwits.com/SelectiveTrader/message/641848445</a>Shares of RILY have jumped 53% over the past year.&nbsp; &nbsp;

Chairman, B. Riley & Co. Bryant Riley (L) and CEO, B. Riley & Co. Tom Kelleher. (Photo by Matt Winkelmeyer/Getty Images)

B.Riley Stock Soars Nearly 40% - What’s Behind The Move?

Company said it has filed its delayed quarterly reports and achieved NASDAQ compliance ahead of the deadline. 

Equity

Company said it has filed its delayed quarterly reports and achieved NASDAQ compliance ahead of the deadline. 


<ul class="summary-bullets"><li>As part of the deal, Bitfarms will receive $9 million in cash upon closing, expected in Q1 2026.</li><li>The CEO said the deal brings forward an estimated 2 to 3 years of free cash flow from operations to be reinvested in our North American HPC/AI energy infrastructure in 2026.</li><li>Bitfarms plans to wind down its Bitcoin mining operations by 2027.</li></ul>Shares of bitcoin miner Bitfarms (<a href="https://stocktwits.com/symbol/BITF">BITF</a>) jumped more than 4% in premarket trading on Friday after it announced that it has entered into a definitive share purchase agreement to sell its 70 MW site in Paso Pe, Paraguay, to the Sympatheia Power Fund (SPF), a crypto infrastructure fund managed by Singapore-based Hawksburn Capital.The deal is valued at $30 million. Bitfarms will receive $9 million in cash upon closing, expected in Q1 2026, and up to $21 million over 10 months following closing, based on certain payment milestones, it stated.The sale of Paso Pe is the culmination of a series of transactions to completely exit LatAm and refocus the company, its management team, and capital on 100% North American power and infrastructure for HPC/AI.“This transaction brings forward an estimated two to three years of anticipated free cash flows from operations to be reinvested into our North American HPC/AI energy infrastructure in 2026,” Ben Gagnon, CEO at Bitfarms, said.<h2 class="st-heading-2">Pivot to HPC</h2>Bitfarms’ pivot into high-performance computing (HPC) and AI infrastructure comes at a time when crypto miners are increasingly struggling to make a profit as energy costs climb and Bitcoin has been showing weakness and thus are adapting to changing market conditions.It’s also not the only company to pivot towards artificial intelligence and high-performance computing. Several firms, including Core Scientific (CORZ), Iren (IREN), Hive Digital (HIVE), and Terawulf (WULF), have also announced similar strategic moves.Bitfarms plans to wind down its Bitcoin mining operations by 2027, and its transition will begin with its 18-megawatt site in Washington State. The company had said the facility would be converted into a liquid-cooled GPU facility designed for Nvidia’s next-generation GB300s.As part of its pivot, its CEO had <a href="https://stocktwits.com/news-articles/markets/equity/bitfarms-slumps-after-q3-miss-ceo-reaffirms-ai-pivot-with-nvidia/cLP92RaRE3m">stated</a> that the company is converting its Washington site and other assets to support AI workloads and cloud operations, backed by the company’s recent $588 million financing round. The core of the plan centers on NVIDIA’s next-generation Vera Rubin GPUs, expected to launch in Q4 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around BITF trended in ‘extremely bearish’ territory amid ‘low’ message volumes.<img src="https://news.stocktwits-cdn.com/bitf_PNG_62282e1d56.webp" alt="bitf.PNG">For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Bitfarms logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

From Bitcoin Mining To AI: What’s Driving BitFarms’ Stock Jump Today?

BitFarms agreed to sell its 70 MW site in Paraguay to a crypto infrastructure fund for $30 million as part of its plans to fully exit LatAm.

What’s Driving BitFarms’ Stock Jump Today

BitFarms agreed to sell its 70 MW site in Paraguay to a crypto infrastructure fund for $30 million as part of its plans to fully exit LatAm.


<ul class="summary-bullets"><li>The sale positions the company to reinvest capital in its core higher-growth segments, OSS said.&nbsp;</li><li>Bressner acquired Bressner for about $5.6 million in October 2018.&nbsp;</li><li>The company now expects revenue of $30 million to $32 million for the full year, marking year-over-year growth of 22% to 30%, in light of the transaction. &nbsp;</li></ul>Shares of One Stop Systems (OSS) jumped 6% after hours on Tuesday after the company announced the sale of all assets and operations of Bressner Technology GmbH and updated its full-year revenue outlook following the transaction.Hardware manufacturer OSS sold Bressner, which it acquired in October 2018, for $22.4 million to Hiper Euro GMBH on Tuesday. The sale positions the company to reinvest capital in its core higher-growth segments including deployable AI, real-time sensor processing, and rugged edge systems engineered for mission-critical defense and commercial environments, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/12/30/3211590/0/en/OSS-Announces-the-Sale-of-Bressner-Technology-GmbH-to-Hiper-Euro-GMBH.html">said.</a>Alongside the divestment, the company said it now expects revenue of $30 million to $32 million for the full year, marking year-over-year growth of 22% to 30%. OSS in November had said that it expects full-year consolidated revenue of $63 million to $65 million, including OSS segment revenue of $30 million to $32 million.<h2 class="st-heading-2">Pivot Into Higher-Growth Segments</h2>Bressner acquired Bressner for about $5.6 million and since then, Bressner has increased annual sales from approximately $18.3 million in 2019 to nearly $33 million on a trailing 12-month basis as of September 30, 2025, the company said.OSS President and CEO Mike Knowles termed the transaction an “important milestone” in the company’s evolution.“With a more focused, streamlined and simplified business, we expect to end 2025 with a significant cash position, no debt, strong year-over-year sales growth, and higher gross margin. We believe these actions establish a powerful foundation to deliver multi-year organic revenue growth of over 20%, higher gross margin, and pursue complementary opportunities that add new customers, technologies, and solutions across our core AI, ML, and edge markets,” Knowles said.<h2 class="st-heading-2">Updated Guidance</h2>Following the transaction, the company now expects positive full year adjusted core profit exclusive of the one-time pre-tax gain of nearly $7.4 million associated with the Bressner transaction.Bressner will be treated as a discontinued operation when the company reports results for the fourth quarter and full year 2025, OSS added.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around OSS jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.A Stocktwits user applauded Tuesday's transaction as “asset-based financing done right.”<stembedurl>https://www.stocktwits.com/Momoware/message/640454421</stembedurl>Another highlighted that the company now has more cash for mergers and acquisitions.<stembedurl>https://www.stocktwits.com/TheBruss/message/640451591</stembedurl><a href="https://stocktwits.com/symbol/OSS">OSS stock</a> has more than doubled this year and over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-starts-cybercab-production-ahead-of-launch-in-2026/cL7IhipREyZ">Tesla Starts Cybercab Production Ahead Of Launch In 2026</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the One Stop Systems (OSS) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

One Stop Systems Stock Rises After Hours On Selling Bressner To Focus On Higher-Growth Segments

Hardware manufacturer OSS sold Bressner, which it acquired in October 2018, for $22.4 million to Hiper Euro GMBH on Tuesday.

<ul class="summary-bullets"><li>Cassava said that it intends to work “expeditiously” with the FDA and address the items flagged by the agency.</li><li>The company added that it no longer expects to initiate the trial in question in the first half of 2026.&nbsp;</li><li>Cassava discontinued Simufilam’s study in mild-to-moderate Alzheimer’s disease in March.</li></ul> Shares of Cassava Sciences, Inc.’s slid a deep 24% on Friday after the U.S. Food and Drug Administration placed a full clinical hold on the proposed proof-of-concept clinical trial for Simufilam in tuberous sclerosis complex -related epilepsy.The stock is now on track for its worst day in about 9 months.The company was informed by the FDA of the hold in a letter earlier this week, it said in a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001069530/000143774925038313/sava20251218_8k.htm">filing</a> with the Securities and Exchanges Commission. The company now has to provide the agency with additional information, including additional pre-clinical data, and modify the protocol design.Cassava said that it intends to work “expeditiously” with the FDA and address the items flagged by the agency. The company added that it no longer expects to initiate the trial in question in the first half of 2026.The company failed to provide a new timing for the study, and said it would depend on its ability to provide the requested information and on satisfactory completion of FDA’s review.<h2 class="st-heading-2">Cassava Hits Multiple Roadblocks With Simufilam</h2>Cassava <a href="https://stocktwits.com/news-articles/markets/equity/cassava-sciences-stock-drops-over-30-percent-after-drug-fails-study/ch7yzVjRbdz">discontinued</a> Simufilam’s study in mild-to-moderate Alzheimer’s disease in March after the drug did not fare better than placebo in reducing cognitive or functional decline in a late-stage study. The company discontinued its efforts to develop the drug for Alzheimer’s disease and phased out the program and then committed to evaluating the drug’s potential in TSC-related epilepsy.Tuberous Sclerosis Complex (TSC) is a rare genetic disorder causing non-cancerous tumors (hamartomas) to grow in many organs, primarily the brain, skin, kidneys, heart, lungs, and eyes. It can lead to symptoms including seizures, developmental delays, intellectual disabilities, and skin abnormalities.According to Austin-based Cassava, TSC affects nearly 50,000 people in the US and epilepsy is one of the most common neurological features of TSC, occurring in 84% of patients. Current therapies for the condition include antiepileptic drugs and mTOR inhibitors which are not fully effective, and are associated with serious adverse events, the company said in November.Cassava decided to study Simufilam in TSC-related epilepsy on the results of two sophisticated studies conducted in animals that support the drug’s potential, CEO Rick Barry said last month. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SAVA fell from ‘bearish’ to ‘extremely bearish' territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.A Stocktwits user highlighted a buying opportunity.<stembedurl>https://www.stocktwits.com/MrStockxy/message/639701864</stembedurl><a href="https://stocktwits.com/symbol/SAVA">SAVA stock</a> has dropped 8% this year and by 5% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/rocket-lab-stock-heads-for-its-best-day-in-over-8-months-rally-isn-t-only-about-trump/cLe0GDaREst">Rocket Lab Stock Heads For Its Best Day In Over 8 Months — And The Rally Isn’t Only About Trump</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Cassava Sciences Stock On Track For Worst Day In About 9 Months — What’s Driving Today’s Selloff?

FDA placed a clinical hold on the proposed proof-of-concept clinical trial for Simufilam in tuberous sclerosis complex -related epilepsy earlier this week.

<ul class="summary-bullets"><li>FueCell's fourth-quarter earnings received a boost from strong demand for electricity amidst the global AI push.</li><li>The company’s fourth-quarter revenue surged past estimates.</li><li>It reported a narrower loss in the quarter compared to the year-ago period.</li></ul>FuelCell Energy (<a href="https://stocktwits.com/symbol/FCEL">FCEL</a>) shares jumped 35% at the opening bell on Thursday after its fourth quarter revenue surged past analyst estimates, helped by increasing demand for electricity and data center projects amidst a global AI push, while its loss came in narrower than expected.&nbsp;As corporations and governments continue to adopt and implement artificial intelligence in their daily operations, the demand for data centers and electricity to keep them running has remained high, helping firms like FuelCell, which provide fuel cell power plants that generate clean electricity for businesses and communities.<h2 class="st-heading-2">&nbsp; Q4 Report</h2>The company reported fourth-quarter (Q4) revenue of $55 million, well above analyst estimates of $47.2 million, according to data from Fiscal.ai.&nbsp;“We believe that our fourth quarter performance and ongoing cost reductions have positioned us well to meet the accelerating demand for electricity and data center projects in the U.S. and internationally,” said Jason Few, President and CEO of FuelCell Energy.The company also posted an adjusted net loss attributable to common stockholders of $29.8 million in the quarter, compared to an adjusted net loss of $35.3 million in the fourth quarter of fiscal 2024. It reported an adjusted net loss per share of $0.83 compared to analysts’ expectation of a loss of $1.09 per share.&nbsp;<h2 class="st-heading-2"> How Did Stocktwits Users React?</h2>On Stocktwits, the retail sentiment around FCEL remained in ‘extremely bullish’ territory, and message volume remained ‘extremely high’. The stock is among the top 10 trending tickers on Stocktwits.&nbsp;<figure class="image"><img style="aspect-ratio:636/76;" src="https://news.stocktwits-cdn.com/Capture_3_PNG_f220001d6f.webp" alt="On Stocktwits, the retail sentiment around FCEL remained in ‘extremely bullish’ territory, and message volume remained ‘extremely high’. " width="636" height="76"></figure>One of the users on Stocktwits sounded “super bullish” on the stock after its earnings report.<figure class="image"><img style="aspect-ratio:648/109;" src="https://news.stocktwits-cdn.com/Capture2_PNG_cf56df1028.webp" alt="One of the users on Stocktwits sounded “super bullish” on the stock after FuelCell's earnings report." width="648" height="109"></figure>FuelCell Energy shares have declined nearly 24% so far in 2025.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp; &nbsp;

In this photo illustration, the FuelCell Energy logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Did FuelCell Stock Rocket 35% Today?

The company reported fourth-quarter revenue of $55 million, well above analyst estimates of $47.2 million, according to data from Fiscal.ai. 

Kezar Life Sciences (KZR) shares rallied 47% on Friday afternoon despite analyst downgrades and price target cuts.Jefferies analyst Maury Raycroft downgraded Kezar Life Sciences to ‘Hold’ from ‘Buy’ with a price target of $7, down from $18. Meanwhile, William Blair analyst Matthew Phipps downgraded Kezar Life Sciences to ‘Market Perform’ from ‘Outperform’ without a price target. Wells Fargo kept its ‘Equal Weight’ rating on the shares but slashed the price target to $5 from $7.Kezar <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.kezarlifesciences.com/news-releases/news-release-details/kezar-life-sciences-announces-regulatory-update-zetomipzomib">announced</a> on Thursday that it has initiated a process to explore strategic alternatives focused on maximizing shareholder value after being unable to align with the U.S. Food and Drug Administration on a potential registrational clinical trial of Zetomipzomib in patients with relapsed and refractory autoimmune hepatitis (AIH). Autoimmune hepatitis is a rare, chronic disease that predominantly affects women and, if left untreated, can lead to cirrhosis, liver failure, and hepatocellular carcinoma.However, the FDA Division of Hepatology and Nutrition cancelled a Type C meeting that was previously scheduled with Kezar in the fourth quarter to discuss a proposed study in AIH, the company said.Earlier this year, Kezar reported positive safety and efficacy data from a clinical trial in patients with refractory or relapsed AIH. However, the regulator requested that Kezar conduct a stand-alone study to define the pharmacokinetics of Zetomipzomib in subjects with significant hepatic impairment before the initiation of another clinical trial in AIH.This study would delay future trials of Zetomipzomib in AIH by approximately two years, the company said, while adding that the requirements put forth by the FDA would also hinder patient enrollment and participation.“While we remain excited about the potential of Zetomipzomib to be the first approved agent in AIH, we lack the resources to extend the development timeline,” CEO Chris Kirk said.The company also said it would be implementing a restructuring plan, including layoffs and other cash conservation measures, as part of the strategic alternative evaluation.William Blair said on Friday that it is surprised to see the FDA refusing to host a Type C meeting. Considering Kezar's current cash balance and liabilities, Blair believes a potential acquisition in the $6 to $7 per share range could be feasible.Wells, however, thinks there could be upside if they return cash to shareholders or in a reverse merger scenario.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/KZR">KZR stock</a> soared from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:589/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_17_at_12_46_33_PM_png_393ca210c9.webp" alt="KZR's Sentiment Meter and Message Volume as of 12:46 p.m. ET on Oct. 17, 2025 | Source: Stocktwits" width="589" height="62"><figcaption>KZR's Sentiment Meter and Message Volume as of 12:46 p.m. ET on Oct. 17, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that $6.50 to $7 would be a good range for the stock.<stembedurl>https://stocktwits.com/StockBoyAri/message/632736011</stembedurl>Another user expressed doubts over the rally.<stembedurl>https://stocktwits.com/CMCanalyst/message/632743196</stembedurl>KZR stock is down by 9% this year and by about 25% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/artiva-biotherapeutics-gets-price-target-hike-from-wedbush/ch6sW9tR38A">Artiva Biotherapeutics Gets A Price Target Hike From Wedbush: Stock Rallies 99% But Retail Expects Further Rally</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive

Kezar announced on Thursday that it was unable to align with the FDA on a potential registrational clinical trial of Zetomipzomib in patients with relapsed and refractory autoimmune hepatitis.

Fossil Group (FOSL) shares were down nearly 39% in premarket trading on Thursday morning after the company said on Thursday that it has further extended the&nbsp;expiration of the exchange offer concerning its 7.00% Senior Notes due 2026.The company also noted that it has extended the consent solicitation and its concurrent rights offering from October 15 to October 22.Separately, the company stated that it is not currently pursuing an initial public offering of its subsidiary in India, following recent media reports about the subsidiary going public.Retail sentiment on Fossil Group jumped to ‘extremely bullish’ from ‘bearish’ territory a day ago, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.On Wednesday, Fossil Group’s shares had closed up 41.5% at a two-and-a-half-year high of $3.75 following the news of the IPO of its Indian unit. According to a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-10-15/fossil-india-is-said-to-weigh-ipo-that-could-raise-400-million">Bloomberg News report</a>, Fossil India was in talks to raise $300 million to $400 million by selling as much as a 25% stake.The report noted that the talks were ongoing and that the size of the IPO or the possible timing of the offering could change.&nbsp;In early 2025, as part of a plan to save costs, the company planned to shut down around 50 retail locations and shift certain international markets to a distributor model. The firm is home to several premium brands such as Fossil Watches and Michele.&nbsp;<a href="https://stocktwits.com/symbol/VERI">Shares of Fossil Group</a> have jumped 125% this year and gained nearly 213% in the last 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/alibaba-executive-reportedly-says-company-beginning-to-see-return-on-ai-investment-in-e-commerce/ch6pRcFR3nf">Alibaba Executive Reportedly Says Company Beginning To See Return On AI Investment In E-Commerce: Forecasts ‘Very Significant’ Positive Impact</a>

Sign of Fossil Group outside a store in Orlando, Florida.

FOSL Stock Plunges After Extending Exchange Offer For Its Senior Notes Due 2026

Separately, the company stated that it is not currently pursuing an initial public offering of its subsidiary in India, following recent media reports about the subsidiary going public.

Shares of TrueCar (TRUE) rallied 60% on Wednesday morning after the company said that it has entered into a definitive agreement under which Fair Holdings, Inc., an entity led by TrueCar founder Scott Painter, will acquire the company in an all-cash, go-private transaction at $2.55 per share.This represents a premium of about 72% from the stock’s closing price on Tuesday and amounts to an equity value of approximately $227 million based on current basic shares outstanding.TrueCar <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/truecar-to-be-acquired-by-founder-led-strategic-and-financial-investor-group-in-all-cash-go-private-transaction-302584766.html">said</a> that Fair Holdings is negotiating with various financial and strategic investors to syndicate the financing of the deal with equity investments.TrueCar Chair Barbara Carbone said that the board unanimously approved the transaction after a thorough and careful evaluation. “...we are confident it is in the best interest of TrueCar stockholders and other stakeholders,” they added.Upon completion of the deal, Scott Painter will be the CEO of the company again, it said. The transaction is expected to close in the fourth quarter of 2025 or early 2026, subject to the receipt of certain approvals. Once the deal is completed, TrueCar will no longer trade on the bourse.However, if Fair Holdings is unable to complete the transaction, it has agreed to pay a reverse termination fee to TrueCar, the company said.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TRUE">TRUE stock</a> jumped from ‘neutral’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:586/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_15_at_1_43_05_PM_png_7f46c96902.webp" alt="TRUE's Sentiment Meter and Message Volume as of 1:43 p.m. ET on Oct. 15, 2025 | Source: Stocktwits" width="586" height="63"><figcaption>TRUE's Sentiment Meter and Message Volume as of 1:43 p.m. ET on Oct. 15, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits applauded the buyout as a “good deal.”<stembedurl>https://stocktwits.com/mickymatthews/message/632395006</stembedurl>Another, however, opined that the price is low.<stembedurl>https://stocktwits.com/mickymatthews/message/632389499</stembedurl>TRUE stock is down by 36% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rigetti-computing-stock-slides-8-after-hitting-record-highs-on-tuesday/ch6F2raR3VG">Rigetti Computing Stock Slides 8% After Hitting Record Highs On Tuesday — Traders Warn Of More Downside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Employees of TrueCar celebrate while ringing the opening bell for the Nasdaq Exchange in Times Square on May 16, 2014 in New York City. TrueCar was having it's initial public offering (IPO) on the Nasdaq exchange. (Photo by Andrew Burton/Getty Images)

TrueCar Shares Soar Following $227M Go-Private Deal

The per share purchase price represents an equity value of $227 million and a premium of about 72% from the stock’s closing price on Tuesday. 

Cellectar Biosciences (CLRB) stock tumbled over 17% on Tuesday after the company announced an agreement with several institutional investors to exercise certain existing warrants for gross proceeds of approximately $5.8 million.Cellectar <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cellectar.com/news-media/press-releases/detail/377/cellectar-biosciences-inc-enters-into-agreements-to-raise">stated</a> that a total of 1.05 million existing warrants were exercised. The company now intends to use the net proceeds for working capital and general corporate purposes in addition to funding the early-stage trial of its CLR 125 compound in triple-negative breast cancer.The capital raise comes on the heels of Cellectar <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cellectar.com/news-media/press-releases/detail/376/cellectar-biosciences-announces-european-medicines-agency">announcing</a> that it intends to submit a conditional marketing authorization application to the European Medicines Agency for Iopofosine I 131 as a treatment for refractory Waldenstrom macroglobulinemia in early 2026, following advice from the agency’s Scientific Advice Working Party (SAWP).The company stated that it anticipates European Approval by 2027 and commercial availability of the therapy in the 30 countries represented by the EMA in the same year.“We believe this regulatory success is substantial as it further supports Cellectar’s plans to pursue worldwide approval, including a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) under an accelerated approval pathway,” CEO James Caruso said on Monday, while noting that an NDA submission is contingent upon the company obtaining additional funding to initiate a confirmatory trial.Oppenheimer, which has a ‘Perform rating’ on <a href="https://stocktwits.com/symbol/CLRB">CLRB shares</a>, subsequently noted that the news is a substantial positive catalyst that should bolster the company’s efforts to partner the Iopofosine I 131 program.On Stocktwits, retail sentiment around CLRB jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1372/132;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_07_at_11_30_27_AM_png_09a789f2e6.webp" alt="CLRB's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Oct. 07, 2025 | Source: Stocktwits" width="1372" height="132"><figcaption>CLRB's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Oct. 07, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user dismissed the decline in the stock price.<stembedurl>https://stocktwits.com/EvenBetter99/message/631308393</stembedurl>Another user expressed hopes about an impending rally in the shares.<stembedurl>https://stocktwits.com/Slab6/message/631300689</stembedurl>CLRB stock is down 43% this year and approximately 92% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ford-shares-slump-after-reports-of-fire-at-aluminum-supplier-plant/ch6PW0NR3ha">Ford Shares Slump 5% After Reports Of Fire At Aluminum Supplier Plant: Retail Dismisses The Dip As ‘Short-Lived’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cellectar Biosciences Stock Drops 17% On $5.8M Fundraise: Retail Awaits An ‘Impending’ Rally

The company announced that it now intends to utilize the net proceeds for working capital and general corporate purposes, in addition to funding the early-stage trial of its CLR 125 compound in triple-negative breast cancer. 

Shares of Lyra Therapeutics, Inc. (LYRA) rose 19% on Monday after the company stated that it intends to proceed with an additional clinical trial for its lead product candidate for chronic rhinosinusitis.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/06/3161569/0/en/Lyra-Therapeutics-Announces-Clinical-Plan-for-LYR-210-and-Late-Breaking-Oral-Presentation-of-Phase-3-ENLIGHTEN-2-Study.html">stated</a> that the U.S. Food and Drug Administration confirmed at a meeting in September that an additional trial was required for the submission of a new drug application for LYR-210 in the treatment of chronic rhinosinusitis without nasal polyps. The design of the new trial will be based on the learnings from previous trials, as well as feedback from the FDA, the company said."We look forward to continuing the development of LYR-210 as a six-month treatment option for millions of patients who do not respond to standard CRS medical management,” CEO Maria Palasis said.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LYRA">LYRA stock</a> stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:1364/130;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_06_at_2_16_16_PM_png_84207e66c2.webp" alt="LYRA's Sentiment Meter and Message Volume as of 2:16 p.m. ET on Oct. 06, 2025 | Source: Stocktwits" width="1364" height="130"><figcaption>LYRA's Sentiment Meter and Message Volume as of 2:16 p.m. ET on Oct. 06, 2025 | Source: Stocktwits</figcaption></figure>In June, Lyra announced positive results from a late-stage trial of LYR-210 in adult patients with CRS. It demonstrated statistically significant improvement compared to sham control in key symptoms of chronic rhinosinusitis, such as nasal obstruction, nasal discharge, and facial pain/pressure at week 24 in patients with or without nasal polyps in the trial.LYR-210 is an investigational bioabsorbable nasal implant for the treatment of chronic rhinosinusitis (CRS) in patients who have failed current therapies and require further intervention. It is designed to be inserted in a simple, in-office procedure and intended to deliver six months of continuous anti-inflammatory therapy, mometasone furoate, to the sinonasal passages for the treatment of CRS.LYRA stock is down 19% this year and approximately 25% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spruce-biosciences-stock-more-than-quadruples-after-breakthrough-therapy-designation-to-therapy-for-rare-fatal-genetic-disease/ch6R7WfR3gl">Why Did Spruce Biosciences Stock Quadruple Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Lyra Therapeutics To Conduct One More Trial For Chronic Rhinosinusitis Treatment Candidate

The company stated that the design of the new trial will be based on the learnings from the previous trials, in addition to FDA feedback.

Dimensional ETF Trust - Dimensional U.S. Small Cap ETF

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

DFAS
Dimensional ETF Trust - Dimensional U.S. Small Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest DFAS News

DFASDimensional ETF Trust - Dimensional U.S. Small Cap ETF